Kexing Biopharm (SHA:688136) renewed its office lease and property management agreements with Chuangyi Biotech for the Chuangyi Technology Building in Shenzhen.
The two-year contract is effective March 1, according to a Tuesday filing with the Shanghai bourse. Total rent is capped at 17.1 million yuan, with property management fees of up to 3.1 million over the term.
Kexing Biopharm and Chuangyi Biotech are controlled by Zhengzhong Investment Group.
Shares of the biopharmaceutical company closed 4% lower Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments